Evidence map›Paper›PMID 35702582›Full record

ArticleIntractable & rare diseases research2022

Atrial invasion from primary lung adenocarcinoma extension

Akshay Machanahalli Balakrishna, Bryton Perman, Mahmoud Ismayl, Dua Noor Butt, Dixitha Anugula, Ahmed Aboeata

Open access · diamondAbstract read
In one paragraph

Article in Intractable & rare diseases research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 92% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Akshay Machanahalli BalakrishnaDivision of Internal Medicine, Creighton University School of Medicine, Omaha, NE, USA.
Bryton PermanDivision of Internal Medicine, Creighton University School of Medicine, Omaha, NE, USA.
Mahmoud IsmaylDivision of Internal Medicine, Creighton University School of Medicine, Omaha, NE, USA.
Dua Noor ButtDivision of Internal Medicine, Creighton University School of Medicine, Omaha, NE, USA.
Dixitha AnugulaDepartment of Cardiology, Houston Methodist DeBakey Heart & Vascular Center, Houston, Texas, USA.
Ahmed AboeataDivision of Cardiovascular Diseases, Creighton University School of Medicine, Omaha, NE, USA.
Creighton University · USHouston Methodist · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intravascular extension of lung adenocarcinoma is one of the four defined routes of metastasis to the heart but is rarely described in the literature. This is a rare case of primary lung adenocarcinoma with intravenous extension to the left atrium via the pulmonary vein. A 56-year-old female presented to the hospital with chest tightness and dyspnea. Chest computed tomography revealed a right hilar mass extending through the right superior pulmonary vein into the left atrium. Transthoracic echocardiography revealed a large, partially mobile left atrial mass occupying the entire atrial cavity and affecting mitral valve closure. Endobronchial ultrasound with transbronchial biopsy of the right middle lobe of the lung histologically showed a poorly differentiated adenocarcinoma compatible with the primary lung cancer. The patient was deemed a poor surgical candidate by cardiothoracic surgery due to the extent of metastasis and was started on chemoradiation. The patient's left atrial tumor mass started shrinking in size after starting the treatment. This unique case displaying intravascular extension of lung cancer to the left atrium has rarely been described in the literature.

Indexed as

invasionleft atriumlung adenocarcinomapulmonary vein

Identifiers

PMID35702582
PMCPMC9161132
OpenAlexW4225556444

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.